IMPC phenotypes (gene matching)
Hprt1-CAG-LSL-ROCK2:ER
| Status | Available to order |
| EMMA ID | EM:11383 |
| International strain name | Hprt1-CAG-LSL-ROCK2:ER |
| Alternative name | Hprt-CAG-LSL-ROCK2:ER |
| Strain type | Targeted Mutant Strains : Conditional mutation |
| Allele/Transgene symbol | Hprt1tm-(CAG-ROCK2/ERT) |
| Gene/Transgene symbol | Hprt1 |
Information from provider
| Provider | Michael Olson |
| Provider affiliation | Cancer Research UK Beatson Institute |
| Genetic information | Hprt1-CAG-LSL-ROCK2:ER |
| Phenotypic information | Homozygous:The Hprt1-CAG-LSL-ROCK2:ER targeted transgene enables cre recombinase-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Given the X-chromosome location, homozygous females have one active copy due to X-chromosome inactivation, while males cannot be homozygous.Heterozygous:Hprt1-CAG-LSL-ROCK2:ER enables cre recombinase-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Males can only be hemizygous, heterozygous females may display mosaic patterns of expression due to X-chromosome inactivation. |
| References | None available |
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
MGI phenotypes (gene matching)
- decreased hematocrit / MGI
- increased leukocyte cell number / MGI
- increased neutrophil cell number / MGI
- abnormal small intestine morphology / MGI
- abnormal liver morphology / MGI
- abnormal branching of the mammary ductal tree / MGI
- enlarged spleen / MGI
- spleen hyperplasia / MGI
- enlarged lymph nodes / MGI
- tremors / MGI
- convulsive seizures / MGI
- abnormal lung morphology / MGI
- decreased body weight / MGI
- decreased anxiety-related response / MGI
- ataxia / MGI
- hypoactivity / MGI
- impaired coordination / MGI
- abnormal gait / MGI
- short stride length / MGI
- decreased exploration in new environment / MGI
- limb grasping / MGI
- abnormal motor coordination/balance / MGI
- abnormal hematopoietic system physiology / MGI
- hyperglycemia / MGI
- anemia / MGI
- cardiac hypertrophy / MGI
- increased mammary adenocarcinoma incidence / MGI
- abnormal reflex / MGI
- seizures / MGI
- abnormal motor capabilities/coordination/movement / MGI
- premature death / MGI
- abnormal definitive hematopoiesis / MGI
- abnormal brain morphology / MGI
- no abnormal phenotype detected / MGI
- neurodegeneration / MGI
- abnormal spleen white pulp morphology / MGI
- abnormal hematopoietic system morphology/development / MGI
- abnormal megakaryocyte progenitor cell morphology / MGI
- hepatic steatosis / MGI
- decreased vertical activity / MGI
- increased heart weight / MGI
- increased systemic arterial blood pressure / MGI
- albuminuria / MGI
- decreased erythrocyte cell number / MGI
- increased urine protein level / MGI
- impaired social transmission of food preference / MGI
- no phenotypic analysis / MGI
- phenotypic reversion / MGI
- abnormal dopaminergic neuron morphology / MGI
- astrocytosis / MGI
- abnormal depression-related behavior / MGI
- decreased tumor growth/size / MGI
- abnormal nervous system morphology / MGI
- abnormal cardiac muscle relaxation / MGI
- neuronal intranuclear inclusions / MGI
- abnormal myocardial fiber physiology / MGI
- abnormal Paneth cell morphology / MGI
- decreased B cell number / MGI
- decreased cardiac muscle contractility / MGI
- glomerulosclerosis / MGI
- abnormal podocyte morphology / MGI
- muscle phenotype / MGI
- homeostasis/metabolism phenotype / MGI
- endocrine/exocrine gland phenotype / MGI
- behavior/neurological phenotype / MGI
- immune system phenotype / MGI
- taste/olfaction phenotype / MGI
- hematopoietic system phenotype / MGI
- jerky movement / MGI
- thrombocytosis / MGI
- decreased ventricle muscle contractility / MGI
- decreased mean corpuscular hemoglobin concentration / MGI
- decreased dopamine level / MGI
- abnormal podocyte slit diaphragm morphology / MGI
- absent podocyte slit diaphragm / MGI
- podocyte foot process effacement / MGI
- increased megakaryocyte cell number / MGI
- abnormal spatial reference memory / MGI
- abnormal spatial working memory / MGI
- abnormal splenic cell ratio / MGI
- abnormal physiological response to xenobiotic / MGI
- abnormal enterocyte proliferation / MGI
- abnormal enterocyte apoptosis / MGI
- abnormal neuron differentiation / MGI
- increased mammary gland tumor incidence / MGI
- myeloid hyperplasia / MGI
- expanded mesangial matrix / MGI
- mesangial cell hyperplasia / MGI
- abnormal habituation to a new environment / MGI
- abnormal ceramide level / MGI
- decreased brain choline acetyltransferase activity / MGI
- decreased brain tyrosine 3-monooxygenase activity / MGI
- decreased vascular endothelial cell proliferation / MGI